Status:
UNKNOWN
Comparative Study of Patterns of Immune Response to COVID 19 Vaccination
Lead Sponsor:
National Research Centre, Egypt
Collaborating Sponsors:
The holding company for biological products and vaccines (VACSERA)
Theodor Bilharz Research Institute
Conditions:
Immune Response to Covid 19 Vaccination
Eligibility:
All Genders
15-70 years
Brief Summary
An effective vaccine stands as the most effective way for controlling the COVID 19 pandemic , yet, immunogenic vaccine efficacy needs to be extensively studied . T cell responses against the structura...
Detailed Description
This proposed project is a joint collaboration between the National Research Center(NRC) , Hematology treatment unit of the holding company for biological products and vaccines (VACSERA) and Theodor B...
Eligibility Criteria
Inclusion
- Both sexes.
- 3 weeks post scheduled first vaccination dose
- Healthy group not suffering from any systemic diseases.
- B thalassemia major splenectomized group
- Signing an informed consent .
Exclusion
- 1- Malignancy of whatever nature. 2- Systemic diseases apart from B thalassemia for the B thalassemia group. 3- Previous infection with COVID 19 . 4- Refusal to sign the informed consent .
- \-
Key Trial Info
Start Date :
June 20 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05408299
Start Date
June 20 2022
End Date
March 1 2023
Last Update
June 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Research Center
Cairo, Dokki, Egypt